Intelligent Ultrasound Share Discussion Threads

[40 fathoms] 19/4/2024 10:26

Cavendish have put out a flash note, no change in target price, I assume if that is coming it will come with the release of the final results.

They state that with the expansion of Sonolystlive to the Voluson Signature 20 that they expect the number of machines on which they will now receive a royalty to be @10,000 per year to that you can add more revenue when it is selected as an optional upgrade on the Swift and Signature 18. They also make the point that there is more to come with the roll out and also other features and product enhancements.

It would now appear that of the @15,000 Voluson machines sold per year we are a standard option on @ 10,000 and available as an option on @3,000.

[eeza] 19/4/2024 07:39

Will it open at 9p offer.

[40 fathoms] 19/4/2024 07:26

Fantastic!

With this news and the additional significant high quality, multi year royalty revenue that it brings, we have turned the corner as a company. This should be confirmed by the results presentation but we can now start to focus on valuation as much as catalysts.

With the significant growth runway ahead of us and given we are tipping in to profitability, 2x this years revenue seems very, very undervalued.

[bmcollins] 19/4/2024 07:09

bamboo & 40fathoms

Thank you both for your frequent posts, todays rns shows how accurate you have both been.
So now we can look forward to 1st of May for the results & what should be a very interesting presentation.

[bamboo2] 19/4/2024 07:07

Notice of results

Analyst and investor briefing



Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces it will issue its audited final results for the year ended 31 December 2023 on Wednesday, 1 May 2024.



A briefing for analysts will be held via Teams on 1 May 2024 at 9.30am. To register, please contact [e-mail]



The Company will host a live presentation for investors given by CEO Stuart Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday, 1 May at 1pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.



Investors can sign up to Investor Meet Company for free and add to meet the Company via:



Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited.

[bamboo2] 19/4/2024 07:05

SonoLyst, powered by Intelligent Ultrasound's ScanNav AI, launches on new GE HealthCare Voluson Signature Series ultrasound machines





Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces that GE HealthCare's SonoLyst software, powered by Intelligent Ultrasound's ScanNav AI, has been launched on the new Voluson Signature Series portfolio of ultrasound machines, the Signature 20 and Signature 18.



SonoLystlive enhances ultrasound image recognition by automatically capturing images in real-time, as the clinician scans a mid-trimester patient. Using practice guidelines from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the AI software automatically recognises the anatomy, captures the image and checks it off the list of required views. By minimising the need to manually freeze, annotate and store images, the software reduces keystrokes by up to 65% and exam time by up to 40% for sonographers.



SonoLystlive will be offered as a standard feature on the Voluson Signature 20 and as an option on the Voluson Signature 18.



Stuart Gall, CEO of Intelligent Ultrasound, commented: "We are pleased that with this launch, SonoLyst, powered by our ScanNav AI software, is now available on three GE HealthCare ultrasound machine ranges -- Expert, Signature and SWIFT. GE HealthCare is leading the way in using AI software to improve obstetric workflows for the benefit of clinicians and patients, while saving scanning time and destressing the scanning environment for sonographers. We remain excited that our novel 'classroom-to-clinic' approach is making clinical diagnostic ultrasound easier to learn and simpler to use."

[bamboo2] 18/4/2024 19:59

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging

*Integrated artificial intelligence (AI) and advanced tools improve image quality and exam speed to help providers make accurate diagnoses and tailor precision care for women

*Latest Voluson Signature ultrasound technology offers an intuitive and ergonomic design allowing clinicians to focus on patient care

April 18, 2024 10:32 AM Eastern Daylight Time

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health. These latest systems combine high-performance hardware with flexible scalable software to help increase clinicians’ confidence in their diagnostic and treatment determinations... [c'ntd]

[40 fathoms] 18/4/2024 05:21

Looks like today is Voluson Signature launch day ....



They give a lot of prominence to Sonolyst and it is clearly a key selling point

Furthermore this is a google translation of a press release put out today by GE Healthcare Japan.

"We will start selling the latest models of the “Voluson series” “Voluson Signature 20” and “Voluson Signature 18” on Thursday, April 18, 2024. Additionally, the product will be exhibited for the first time at the 76th Academic Conference of the Japanese Society of Obstetrics and Gynecology, which will be held from Friday, April 19, 2024."

We should get a confirmatory RNS from the Company in the very near future !

[40 fathoms] 13/4/2024 01:13

A floating charge has been registered by HSBC at Companies House. This strongly suggests that we are in the process of obtaining some form of debt facility.

Firstly, I think it is very good news that a traditional lender such as HSBC sees us as creditworthy and we have clearly been able to demonstrate to them a repayment ability. At very least we will have had to demonstrate cash flow positivity in the near term.

Secondly, although cash flow positivity is close at hand it will take 12 to 18 months to get to the position where we are generating sufficient levels of free cash flow to allow meaningful new investment in the business. It seems sensible to me that we would give ourselves the flexibility to accelerate investment in to the development portfolio including liver and fetalcheck and/or in to additional sales resources. The alternative would be to delay these type of investments by 12 to 18 months until the cash flows allowed it.

While we still need to see the size and terms of the facility as this is HSBC they are likely to be sensible. I think this may well mark the transition of IUG from a start up to an established business.

[40 fathoms] 08/4/2024 08:28

I suspect Eeza is correct, it seems like the Signature launch is imminent so I assume the launch details becoming public would be the trigger for an announcement.

[eeza] 08/4/2024 06:54

Probably with the results announcement ~22 April

[bmcollins] 08/4/2024 06:18

@40Fathoms
Thanks again for your updates, they have always been accurate & illuminating.
I wonder when we might see an announcement along these lines from the board ?

[40 fathoms] 08/4/2024 00:45

This news all but confirms, that at least on a run rate basis, we should reach cash flow positivity this year and should be meaningfully cash flow positive next year.

Once this is confirmed, from a share price perspective, I think we enter a different paradigm.

Breakeven seems to be between 16 & 17 million. The way I look at FY25 is that if we assume 10% growth in simulation sales in to FY2025 and the anticipated GE royalty revenue that takes up to breakeven. Any revenue from ScanNav PNB, Needletrainer, FetalCheck, Gestational Age & Military applications in RA will all fall to the bottom line. It is probably too early for liver products to have any impact but that has the potential to be very significant indeed, especially in light of Madrigals FDA approval of a first in class NASH drug and a encouraging results from a host of others who are one or two years behind them.

[40 fathoms] 06/4/2024 03:36

I have good news !



The first service manual you will see is for the FDA approved but yet to be launched Voluson Signature 18-20.

If you open the file and search on Sonolyst or Sonolyst live you will see that in the table in section 5.1.2 (page 5-9), that both are to be included as standard on the Signature 20 model and as optional extra on the Signature 18 model. I note that all software modules are optional on the 18 so this is obviously the bare bones variant and the vast majority of the sales are likely to be for the 20.

Once launched and on an annualised basis this should almost double the royalty income received from GEHC to the US$4.75/$5 million per annum level. With more to come as they complete the Sonolyst roll out across the fleet and introduce earlier and later protocol based scans. Also, we still have the 2nd product under development which was covered by a seperate agreement signed in Jan 22. Lastly there is also the possibility that GE looks to pick up the Gestational Age product.

[bamboo2] 02/4/2024 19:40

HQ.MED.ED has invested in Intelligent Ultrasound’s BodyWorks Eve, HeartWorks and NeedleTrainer as part of the ‘Minnesota point of care ultrasound project’ to educate thousands of healthcare professionals in rural areas across the state.



HQ.MED.ED (High Quality Medical Education) was founded more than 20 years ago as a group of emergency medicine physicians providing medical training courses. Based out of Hennepin County Medical Center, the busiest trauma center in Minnesota, the organization now offers multiple courses across emergency medicine and is pioneering a new project to teach point-of-care ultrasound (PoCUS) to rural practitioners in underserved areas across Minnesota.

The three-year, $6 million project is made possible by funding from a philanthropic group with an emphasis on improving rural healthcare and availability of services... more

[chester9] 02/4/2024 15:40

Results due in April with known guidance. They need to avoid another raise which they have told us they will. This being AIM always taken with a pinch of salt..If they can get profitable before GE or other takes over, it will be better for holders. GE may of course take the opportunity to differ. Not long now to wait.

[bamboo2] 02/4/2024 08:46

MIM deal completed by GEHC. No price mentioned, will have to wait for a financial update to find out.

[bmcollins] 26/3/2024 16:16

40F
Another very useful post, we only need a couple of Fund Managers to take a stake and we're off to the races
Thanks for posting this

[eeza] 23/3/2024 11:39

Finals were 20 April last year, so maybe 4 weeks time for this years finals.

Post Y/E items may give more insight to the African trials above.

Jan's TU mentioned: "ScanNav FetalCheck development programme announced for new gestational age AI product in Q4 2023", and

"Revenue from women's health-related AI software sales, which included both GE HealthCare royalty income combined with non-GE HealthCare revenue from studies utilising our gestational age AI software, made up over half of our clinical AI related sales."




















;

[40 fathoms] 23/3/2024 01:13

Bamboo@ There are many positive qualities I like about IUG but one of the things that I like the me most is that they are always upgrading and adding functionality to their product range. For a small company with limited resources they do this incredibly well. I have no doubt if they get this product to market, some of the possible features you suggest and more will be added overtime.

[bamboo2] 22/3/2024 18:33

40F, just to add to this story, once an ultrasound image or vid exists in the digital realm, it can then in theory be instantly transmitted anywhere in the world. This means that potential problems identified by AI can be forwarded to a real doctor for a confirmatory diagnosis, and subsequent treatment.